LLY

1,063.53

+1.68%↑

JNJ

205.43

+1.03%↑

ABBV

237.6

+3.53%↑

UNH

321

+2.95%↑

AZN

91.8

+3.47%↑

LLY

1,063.53

+1.68%↑

JNJ

205.43

+1.03%↑

ABBV

237.6

+3.53%↑

UNH

321

+2.95%↑

AZN

91.8

+3.47%↑

LLY

1,063.53

+1.68%↑

JNJ

205.43

+1.03%↑

ABBV

237.6

+3.53%↑

UNH

321

+2.95%↑

AZN

91.8

+3.47%↑

LLY

1,063.53

+1.68%↑

JNJ

205.43

+1.03%↑

ABBV

237.6

+3.53%↑

UNH

321

+2.95%↑

AZN

91.8

+3.47%↑

LLY

1,063.53

+1.68%↑

JNJ

205.43

+1.03%↑

ABBV

237.6

+3.53%↑

UNH

321

+2.95%↑

AZN

91.8

+3.47%↑

Search

Cerus Corp

Abrir

SetorSaúde

1.61 5.23

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.45

Máximo

1.6600000000000001

Indicadores-chave

By Trading Economics

Rendimento

5.7M

-19K

Vendas

253K

53M

EPS

-0

Margem de lucro

-0.036

Funcionários

614

EBITDA

5.7M

2.6M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+202.01% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.5M

294M

Abertura anterior

-3.62

Fecho anterior

1.61

Sentimento de Notícias

By Acuity

38%

62%

128 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Cerus Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de nov. de 2025, 23:07 UTC

Conversa de Mercado

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 de nov. de 2025, 22:22 UTC

Conversa de Mercado

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 de nov. de 2025, 22:08 UTC

Conversa de Mercado

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 de nov. de 2025, 21:57 UTC

Ganhos

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 de nov. de 2025, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

20 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

20 de nov. de 2025, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

20 de nov. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

20 de nov. de 2025, 21:31 UTC

Ganhos

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 de nov. de 2025, 21:23 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 de nov. de 2025, 21:07 UTC

Ganhos

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 de nov. de 2025, 21:06 UTC

Ganhos

Webull 3Q Rev $156.9M >BULL

20 de nov. de 2025, 21:06 UTC

Ganhos

Webull 3Q EPS 7c >BULL

20 de nov. de 2025, 21:05 UTC

Ganhos

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 de nov. de 2025, 21:04 UTC

Ganhos

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 de nov. de 2025, 21:04 UTC

Ganhos

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 de nov. de 2025, 21:04 UTC

Ganhos

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit 1Q Consumer Rev $894M

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Backs FY26 Guidance

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 de nov. de 2025, 21:00 UTC

Ganhos

Intuit 1Q Global Business Solutions Rev $3B

Comparação entre Pares

Variação de preço

Cerus Corp Previsão

Preço-alvo

By TipRanks

202.01% parte superior

Previsão para 12 meses

Média 4.5 USD  202.01%

Máximo 5 USD

Mínimo 4 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Cerus Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

3

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.3 / 1.36Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

128 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
help-icon Live chat